Clinical Trial Update: Org 25935 Versus Placebo as Augmentation to Cognitive-behavioral Therapy to Treat Panic Disorder (P05705) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Org 25935 versus placebo as augmentation to cognitive-behavioral therapy for panic disorder; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Panic Disorder

Drugs mentioned

• Org 25935

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Panic Disorder | Phase 2 | Status: TERMINATED | Results posted: 2016-12-30